How should we analyse FDG PET studies for monitoring tumour response?

  • Adriaan A. Lammertsma
  • Corneline J. Hoekstra
  • Giuseppe Giaccone
  • Otto S. Hoekstra
 

DOI: 10.1007/s00259-006-0131-5

Cite this article as:
Lammertsma, A.A., Hoekstra, C.J., Giaccone, G. et al. Eur J Nucl Med Mol Imaging (2006) 33(Suppl 1): 16. doi:10.1007/s00259-006-0131-5

Abstract

FDG PET is a promising technique for monitoring tumour response early during anticancer therapy. Progress, however, has been limited owing to the multitude of methods currently in use. Here, the most promising techniques for multi-centre trials are discussed briefly, with emphasis on the need for standardisation. In addition, an approach is presented for response monitoring studies using newly developed drugs. This approach makes use of a large database of response monitoring studies, which defines the relationship between simplified clinical methods and full quantitative analysis for classic cytotoxic drugs. For a new drug, first a pilot study is performed to assess whether it affects this relationship. Based on this pilot, it is decided whether or not a simplified clinical method can be used in further studies.

Keywords

Multi-centre trials Standardisation Response monitoring FDG PET 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Adriaan A. Lammertsma
    • 1
  • Corneline J. Hoekstra
    • 2
  • Giuseppe Giaccone
    • 3
  • Otto S. Hoekstra
    • 1
  1. 1.Department of Nuclear Medicine and PET ResearchVU University Medical CentreAmsterdamThe Netherlands
  2. 2.Department of Nuclear MedicineJeroen Bosch Hospital‘s-HertogenboschThe Netherlands
  3. 3.Department of Medical OncologyVU University Medical CentreAmsterdamThe Netherlands